Outcomes of subsequent treatment regimens after trastuzumab deruxtecan in patients with metastatic breast cancer

Journal:

Journal of the National Cancer Institute

Published:

2025-08-14

DOI:

10.1093/jnci/djaf220

Affiliations:

9

Authors:

15

Go to article

Institutions	Authors	Share
Yale Cancer Center, United States of America (USA)	3.000000	0.20
Yale University, United States of America (USA)	3.000000	0.20
Dana-Farber Cancer Institute (DFCI), United States of America (USA)	2.250000	0.15
Dana-Farber/Brigham and Women’s Cancer Center (DF/BWCC), United States of America (USA)	2.250000	0.15
Harvard Medical School (HMS), United States of America (USA)	2.250000	0.15
Health Sciences, Pitt, United States of America (USA)	1.000000	0.07
Institute Gustave-Roussy (IGR), France	1.000000	0.07
University of Milan (UNIMI), Italy	0.250000	0.02

Interested in Oncology and Carcinogenesis?